Adverse events in HEAAL: when to hold and when to fold
dc.contributor.author | Pitt, Bertram | en_US |
dc.date.accessioned | 2014-03-05T18:19:12Z | |
dc.date.available | 2014-03-05T18:19:12Z | |
dc.date.issued | 2012-12 | en_US |
dc.identifier.citation | Pitt, Bertram (2012). "Adverse events in HEAAL: when to hold and when to fold." European Journal of Heart Failure 14(12): 1319-1321. <http://hdl.handle.net/2027.42/106139> | en_US |
dc.identifier.issn | 1388-9842 | en_US |
dc.identifier.issn | 1879-0844 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/106139 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.title | Adverse events in HEAAL: when to hold and when to fold | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Cardiovascular Medicine | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23159580 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/106139/1/ejhfhfs167.pdf | |
dc.identifier.doi | 10.1093/eurjhf/hfs167 | en_US |
dc.identifier.source | European Journal of Heart Failure | en_US |
dc.identifier.citedreference | Konstam MA Neaton JD Dickstein K Drexler H Komajda M Martinez FA Riegger GA Malbecq W Smith RD Guptha S Poole‐Wilson PA Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized double‐blind trial Lancet 2009 374 1840 1848 | en_US |
dc.identifier.citedreference | Pitt B Poole‐Wilson PA Segal R Martinez FA Dickstein K Camm AJ Konstam MA Riegger G Klinger GH Neaton J Sharma D Thiyagarajan B Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II Lancet 2000 355 1582 1587 | en_US |
dc.identifier.citedreference | Kierman MS Wentworth D Francis G Martinez FA Dickstein K Komajda M Zannad F Neaton JD Konstam M Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial Eur J Heart Fail 2012 14 1401 1409 | en_US |
dc.identifier.citedreference | Albert NM Yancy CW Liang L Zhao X Hernandez AF Peterson ED Cannon CP Fonarow GC Use of aldosterone antagonists in heart failure JAMA 2009 302 1658 1665 | en_US |
dc.identifier.citedreference | Piit B McMurray J Krum H van Veldhuisen DJ Swedberg K Pocock S Zannad F The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: an analysis of the ‘high‐risk subgroups’. Presented at the ESC Hotline Session 29 August 2011 Paris | en_US |
dc.identifier.citedreference | Authors /Task Force Members McMurray JJ Adamopoulos S Anker SD Auricchio A Böhm M Dickstein K Falk V Filippatos G Fonseca C Sanchez MA Jaarsma T Køber L Lip GY Maggioni AP Parkhomenko A Pieske BM Popescu BA Rønnevik PK Rutten FH Schwitter J Seferovic P Stepinska J Trindade PT Voors AA Zannad F Zeiher A Bax JJ Baumgartner H Ceconi C Dean V Deaton C Fagard R Funck‐Brentano C Hasdai D Hoes A Kirchhof P Knuuti J Kolh P McDonagh T Moulin C Popescu BA Reiner Z Sechtem U Sirnes PA Tendera M Torbicki A Vahanian A Windecker S; Document Reviewers McDonagh T Sechtem U Bonet LA Avraamides P Ben Lamin HA Brignole M Coca A Cowburn P Dargie H Elliott P Flachskampf FA Guida GF Hardman S Iung B Merkely B Mueller C Nanas JN Nielsen OW Orn S Parissis JT Ponikowski P ESC Committee for Practice Guidelines (CPG) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 2012 14 803 869 2012 | en_US |
dc.identifier.citedreference | Butler J Ezekowitz JA Collins SP Givertz MM Teerlink JR Walsh MN Albert NM Westlake Canary CA Carson PE Colvin‐Adams M Fang JC Hernandez AF Hershberger RE Katz SD Rogers JG Spertus JA Stevenson WG Sweitzer NK Tang WH Stough WG Starling RC Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guideline Committee J Card Fail 2012 18 265 281 | en_US |
dc.identifier.citedreference | Vardenay O Wu D‐H Claggett B Desai A Rossignol P Zannad F Pitt B Solomon SC Incidence, predictors and outcomes related to hypo‐ and hyperkalemia in severe heart failure patients treated with an aldosterone blocker J Card Fail 2012 18 S81 | en_US |
dc.identifier.citedreference | Montague BT Ouellette JR Buller GK Retrospective review of the frequency of ECG changes in hyperkalemia Clin J Am Soc Nephrol 2008 3 324 330 | en_US |
dc.identifier.citedreference | Boyd DW Red‐blood cell potassium and aldosteronism Lancet 1970 295 594 595 | en_US |
dc.identifier.citedreference | Mak G Murphy NH Ali A Walsh A O'Loughlin C Conlon C McCaffrey D Ledwidge M McDonald K Multiple neurohumeral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail 2008 14 555 560 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.